<DOC>
	<DOCNO>NCT03000608</DOCNO>
	<brief_summary>This trial double-blind , single-center , randomize , placebo control study evaluate safety , tolerability , efficacy SAN021 study drug administer 42 day adult age 18 65 year clinical diagnosis mild-to-moderate plaque psoriasis .</brief_summary>
	<brief_title>Trial Treatment Mild-to Moderate Plaque Psoriasis Adults</brief_title>
	<detailed_description>Patients enter Screening Period inform consent photographic consent process complete . Patients mild-to-moderate plaque psoriasis , define Psoriasis Area Severity Index ( PASI ) score 2 12 , 36 appropriate topical treatment cover minimum 0.5 % maximum 10 % BSA , permit treatment area , meet inclusion none exclusion criterion enrol . Once subject eligibility confirm screening procedure complete , enrolled subject start Treatment Period study . All enrolled subject receive either 10 % SAN021 placebo serum ( randomized 2:1 ratio ) first dose apply Day 1 Study Visit . Subjects instruct apply study medication twice daily 42 day . Subjects return clinic study-related assessment Study Days 8 , 15 , 29 final visit Day 43 . On Study Day 50 , subject receive Follow-up phone call query condition status since go study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Are ≥18 ≤65 year age Have clinical diagnosis mildtomoderate plaque psoriasis , define Psoriasis Area Severity Index ( PASI ) score 2 12 , 36 appropriate topical treatment cover minimum 0.5 % maximum 10 % Body Surface Area ( BSA ) , permit treatment area . Are willing treat psoriasis occur permit treatment area SAN021 Are free systemic dermatologic disorder , , opinion investigator , interfere study result increase risk adverse event . Are willing avoid prolonged exposure treatment area ultraviolet radiation ( natural artificial ) duration study . Are willing refrain use lotion , moisturizer , cleanser , cosmetic cream , issue part study , treatment area treatment period . If female childbearing potential , must willing practice acceptable form birth control duration study . Are able give write informed consent manner approve Institutional Review Board Ethics Review Committee comply requirement study . Are willing avoid participation clinical trial duration study . Are willing refrain treating restrict area , exclude assessment Body Surface Area ( BSA ) calculation . These area follow : head , neck , fingernail , toenail , sol foot , palm hand , axilla , intertriginous area . Have spontaneously improve rapidly deteriorate plaque psoriasis , pustular psoriasis determine Investigator . Have treat , prescription medication plaque psoriasis , improvement condition , within 60 day prior Baseline visit . Are pregnant , breastfeeding , plan become pregnant study . Have evidence systemic cancer , squamous cell carcinoma , basal cell carcinoma , confound skin condition . Are undergo treatment topical antipsoriatic drug product corticosteroid within 14 day prior Baseline Visit , therapy contain corticosteroid retinoids within 28 day prior Baseline Visit . Have open sore open lesion treatment area ( ) . Have condition , opinion investigator , would confound safety and/or efficacy assessment plaque psoriasis . Have participate interventional clinical trial previous 30 day . Have know sensitivity constituent test product include sensitivity sandalwood oil , fragrance , member Compositae family vascular plant ( e.g. , sunflower , daisy , dahlia , etc. ) . Have use , use , plan use immunosuppressive immunomodulatory medication ( i.e. , biologics ) , include oral parenteral corticosteroid . Have history alcohol illegal drug/substance abuse , suspect alcohol illegal drug/substance abuse past two year . Plan seek alternative treatment kind psoriasis , eligible treatment area otherwise , trial period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>